litlas
Log inCreate account

Charles E. Geyer

Active 1987–2025

114
Papers
47,535
Citations
74
h-index
110
i10-index

Citations

Citations per year for Charles E. Geyer1974: 1 citations1981: 1 citations1982: 2 citations1986: 1 citations1990: 2 citations1991: 1 citations1992: 1 citations1993: 3 citations1996: 1 citations1997: 2 citations1998: 2 citations1999: 10 citations2000: 4 citations2001: 9 citations2002: 8 citations2003: 14 citations2004: 10 citations2005: 25 citations2006: 97 citations2007: 216 citations2008: 286 citations2009: 303 citations2010: 321 citations2011: 285 citations2012: 282 citations2013: 307 citations2014: 277 citations2015: 368 citations2016: 360 citations2017: 325 citations2018: 333 citations2019: 1,353 citations2020: 1,476 citations2021: 1,454 citations2022: 1,343 citations2023: 999 citations2024: 1,662 citations2025: 821 citations2026: 26 citations1975–1980: no citations, so these years are not shown1983–1985: no citations, so these years are not shown1987–1989: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,904 citing papers, 25.6% of this breakdownChina: 1,312 citing papers, 8.6% of this breakdownItaly: 967 citing papers, 6.3% of this breakdownUnited Kingdom: 880 citing papers, 5.8% of this breakdownGermany: 769 citing papers, 5% of this breakdownCanada: 603 citing papers, 4% of this breakdownFrance: 601 citing papers, 3.9% of this breakdownSpain: 553 citing papers, 3.6% of this breakdownSwitzerland: 445 citing papers, 2.9% of this breakdownBelgium: 415 citing papers, 2.7% of this breakdownAustralia: 408 citing papers, 2.7% of this breakdownNetherlands: 404 citing papers, 2.6% of this breakdown
0%25.6%Other 26.3%

Institutions

Fields

  • Medicine52.8%
  • Biochemistry, Genetics and Molecular Biology39.5%
  • Computer Science2%
  • Immunology and Microbiology1.4%
  • Health Professions1.1%
  • Materials Science0.6%
  • Other2.6%

Topics

  • Breast Cancer Treatment Studies13.6%
  • HER2/EGFR in Cancer Research10.2%
  • Advanced Breast Cancer Therapies4.4%
  • Breast Lesions and Carcinomas4.3%
  • Cancer Treatment and Pharmacology3.5%
  • Monoclonal and Polyclonal Antibodies Research3.1%
  • Other60.9%

Coauthors

All papers

Open in search
  1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Authors: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 cited by 4,710

  2. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Authors: Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer - New England Journal of Medicine 2018 cited by 2,618

  3. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

    Authors: Andrew Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, Elżbieta Senkus, Jennifer M. Suga, Zhimin Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita K. Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer - New England Journal of Medicine 2021 cited by 1,665

  4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Sibylle Loibl, Fabrice André, Thomas Bachelot, Carlos H. Barrios, Jonas Bergh, Harold J. Burstein, Maria João Cardoso, Lisa A. Carey, Shaheenah Dawood, Lucia Del Mastro, Carsten Denkert, Eva Maria Fallenberg, Prudence A. Francis, H. Gamal‐El‐Din, Karen A. Gelmon, Charles E. Geyer, Michael Gnant, Valentina Guarneri, Sudeep Gupta, Sung‐Bae Kim, David Krug, Miguel Martín, Icro Meattini, Monica Morrow, Wolfgang Janni, Shani Paluch–Shimon, Ann H. Partridge, Philip Poortmans, Lajos Pusztai, Meredith M. Regan, Joseph A. Sparano, Tanja Španić, Sandra M. Swain, Sergei Tjulandin, Masakazu Toi, Dario Trapani, Andrew Tutt, B. Xu, Giuseppe Curigliano, Nadia Harbeck - Annals of Oncology 2023 cited by 844

  5. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2018 cited by 2,369

  6. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Authors: Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross, Priya Rastogi, Karen Cui, Amal Arahmani, Gursel Aktan, Anne Armstrong, Mónica Arnedos, Judith Balmaña, Jonas Bergh, Judith M. Bliss, Suzette Delaloge, Susan M. Domchek, Andrea Eisen, F. Elsafy, L.E. Fein, Anitra Fielding, James M. Ford, Sue Friedman, Karen A. Gelmon, Luca Gianni, Michael Gnant, Simon J. Hollingsworth, Seock‐Ah Im, Agnes Jager, Oskar T. Johannsson, Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447

  7. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

    Authors: Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark - New England Journal of Medicine 2005 cited by 5,353

  8. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Authors: Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo, Mark D. McKee, Jens Huober, Mehra Golshan, Gϋnter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, José Ponce, Otto Metzger, Priya Rastogi, W. Fraser Symmans, Xuan Liu, Charles E. Geyer - The Lancet Oncology 2018 cited by 771

  9. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Authors: Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron - New England Journal of Medicine 2006 cited by 3,461

  10. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Authors: Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Crown, Jonathan Polikoff, Jean-François Boileau, Louise Provencher, Christopher Stokoe, Timothy D. Moore, André Robidoux, Patrick J. Flynn, Virginia F. Borges, Kathy S. Albain, Sandra M. Swain, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2019 cited by 420

  11. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

    Authors: Rosie Bradley, Jeremy Braybrooke, Richard J. Gray, Robert K. Hills, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard D. Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno‐Aspitia, Martine Piccart, Michael F. Press, Edward H. Romond, Dennis J. Slamon, Vera J. Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard and 1 more - The Lancet Oncology 2021 cited by 348

  12. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

    Authors: Priya Rastogi, Stewart Anderson, Harry D. Bear, Charles E. Geyer, Morton S. Kahlenberg, André Robidoux, Richard G. Margolese, James L. Hoehn, Victor G. Vogel, Shaker R. Dakhil, Deimante Tamkus, Karen King, Eduardo R. Pajon, Mary Wright, Jean Robert, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2008 cited by 1,803

  13. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

    Authors: Charles E. Geyer, William M. Sikov, Jens Huober, Hope S. Rugo, Norman Wolmark, J. O’Shaughnessy, David Maag, Michael Untch, Mehra Golshan, José Ponce, Otto Metzger, Martin Dunbar, W. Fraser Symmans, Priya Rastogi, Joohyuk Sohn, Robyn R. Young, Gail S. Wright, C. Harkness, Kristi McIntyre, Denise A. Yardley, Sibylle Loibl - Annals of Oncology 2022 cited by 219

  14. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Authors: Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Eva Ciruelos, Harold J. Burstein, Hervé Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E. Geyer, Matthew P. Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel Ángel Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E. Davidson, Robert L. Coleman, Marc Debled, Stefan Buchholz, James N. Ingle, Eric P. Winer, Rudolf Maibach, Manuela Rabaglio, Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673

  15. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Authors: Olivia Pagani, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis - Journal of Clinical Oncology 2022 cited by 154

  16. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2019 cited by 555

  17. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  18. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

    Authors: Soonmyung Paik, Gong Tang, Steven Shak, Chungyeul Kim, Joffre Baker, Wanseop Kim, Maureen Cronin, Frederick L. Baehner, Drew Watson, John Bryant, Joseph P. Costantino, Charles E. Geyer, D. Lawrence Wickerham, Norman Wolmark - Journal of Clinical Oncology 2006 cited by 2,577

  19. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Jürg Bernhard, Weixiu Luo, Karin Ribi, Giuseppe Viale, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis - New England Journal of Medicine 2014 cited by 747

  20. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Authors: Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, George W. Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, Sandra M. Swain, Eric P. Winer, Gerardo Colón‐Otero, Nancy E. Davidson, E. Mamounas, Jo Anne Zujewski, Norman Wolmark - Journal of Clinical Oncology 2014 cited by 998

  21. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Prudence A. Francis, Meredith M. Regan, Gini F. Fleming, István Láng, Eva Ciruelos, Meritxell Bellet, Hervé Bonnefoi, Miguel Ángel Climent, Gian Antonio Da Prada, Harold J. Burstein, Silvana Martino, Nancy E. Davidson, Charles E. Geyer, Barbara Walley, Robert E. Coleman, Pierre Kerbrat, Stefan Buchholz, James N. Ingle, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Marco Colleoni, Giuseppe Viale, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber - New England Journal of Medicine 2014 cited by 727

  22. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

    Authors: Eleftherios P. Mamounas, Michael Untch, Max S. Mano, Chiun‐Sheng Huang, Charles E. Geyer, Gϋnter von Minckwitz, Norman Wolmark, Xavier Pivot, Sherko Küemmel, Michael P. DiGiovanna, Bella Kaufman, Georg Kunz, Alison Conlin, Juan Carlos Alcedo, Thorsten Kuehn, Irene Wapnir, Andrea Fontana, John Hackmann, Jonathan Polikoff, Mahasti Saghatchian, Adam Brufsky, Youngsen Yang, Martina Zimovjanová, Thomas Boulet, H. Liu, David Tesarowski, Lisa H. Lam, Chunyan Song, Melanie C. Smitt, Sibylle Loibl - Annals of Oncology 2021 cited by 123

  23. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

    Authors: Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D. Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortés, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, on behalf of the CTNeoBC project - Journal of Clinical Oncology 2023 cited by 96

  24. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Authors: Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi, Sandra M. Swain, Charles E. Geyer, Michael S. Ewer, Vikas Rathi, Louis Fehrenbacher, Adam Brufsky, Catherine A. Azar, Patrick J. Flynn, John L. Zapas, Jonathan Polikoff, Howard M. Gross, David D. Biggs, James N. Atkins, Elizabeth Tan-Chiu, Ping Zheng, Greg Yothers, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2012 cited by 519